The large global burden of respiratory syncytial virus (RSV) respiratory
tract infections in young children and older adults has gained
increased recognition in recent years. Recent discoveries regarding
the neutralization-specifc viral epitopes of the pre-fusion RSV
glycoprotein have led to a shift from empirical to structure-based design
of RSV therapeutics, and controlled human infection model studies
have provided early-stage proof of concept for novel RSV monoclonal
antibodies, vaccines and antiviral drugs.
